🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07376603
Recruiting Observational

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

NCT07376603 · tracked via the Priya Life Science China tracker
Sponsor
Qiaojuan Guo
Phase
Observational
Started
2026-01-12
Last updated
2026-01-29

Condition(s) studied

Nasopharyngeal Cancinoma (NPC)Intensity-modulated RadiotherapyStage IB

Investigational drug(s) / intervention(s)

IMRT along

IMRT along: All patients administered with definitive radiotherapy

Study summary

This observational study aims to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone in patients with stage IB nasopharyngeal carcinoma (NPC) without high-risk features. The primary objective is to determine the therapeutic effectiveness of this approach

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: 1\. Histopathologically confirmed, newly diagnosed nasopharyngeal carcinoma 3. Age 18-70 years 4. Stage IB disease (T1-2N1M0) per the 9th edition AJCC/UICC staging system 5. Upper-neck nodal metastasis only: inferior border of every positive node at or above the inferior border of the hyoid bone 6. ECOG performance status 0-2 7. Adequate bone-marrow function Exclusion Criteria: 1. Age \> 70 years or \< 18 years 2. Matted lymph nodes: two or more contiguous nodes with loss of intervening fat planes and/or extracapsular extension forming a confluent mass 3. Largest metastatic lymph-node ≥ 3 cm in the longest dimension 4. Lower-neck nodal metastasis: inferior border of any positive node below the inferior border of the hyoid bone 5. Prior malignancy except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix 6. Pregnancy or lactation (serum pregnancy test required for women of child-bearing potential; effective contraception mandatory during treatment) 7. Previous radiotherapy to the head-and-neck region 8. Prior chemotherapy or surgery for the primary tumour or metastatic nodes (diagnostic procedures excluded) 9. Any severe comorbidity that would confer unacceptable risk or compromise protocol adherence, including but not limited to unstable cardiac disease, renal failure, chronic hepatitis, or uncontrolled psychiatric disorder 10. History of severe hypersensitivity reactions

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fujian Cancer Hospital Fuzhou Fujian Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07376603 on ClinicalTrials.gov ↗ ← All trials in China